Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7298
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    82.81
    0.00 (0.00%)
     
  • Bitcoin CAD

    88,104.08
    -2,895.84 (-3.18%)
     
  • CMC Crypto 200

    1,385.58
    -38.52 (-2.71%)
     
  • GOLD FUTURES

    2,328.10
    -10.30 (-0.44%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,468.75
    -195.75 (-1.11%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Why This FDA Approval Is a Game Changer for Eli Lilly

Why This FDA Approval Is a Game Changer for Eli Lilly

Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.